According to a new BioPharma Dive analysis, corporate-related funds such as Novo Holdings, Eli Lilly and Sanofi Ventures have ...
Highlights New analysis of ATH434-201 double blind trial strengthens efficacy signal at high dose levelPositive data from ATH434-202 open-label ...
IDEAYA Biosciences, Inc. , a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on October 30, 2025, the Compensation ...
Scientists have co-developed the world’s first product-ready, lab-produced, recombinant snakebite antivenom that protects ...
ChemDiv, a global provider of integrated drug discovery solutions, today announced kinase inhibitor design enhancements to its discovery platform. The new capabilities strengthen support for partners ...
The paper features a comprehensive evaluation of data, including disease control rate, overall survival, immune activation, ...
Is Tango Therapeutics Stock a Buy, Sell, or Hold After Major Shareholder Third Rock Ventures Sold Nearly Half a Million ...
LOS ANGELES, CALIFORNIA / ACCESS Newswire / October 30, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into ...
Phase Ib/IIa study found VES001, the first oral therapy being tested in FTD, led to >95% mean increase in progranulin levels in CSF, compared to ...
Dietary habits linked to Parkinson’s risk: sweets, processed meats raise risk, fruit lowers them, Study finds Scientists have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback